Lion's Mane vs. Ginkgo Biloba for Memory: What the Research Shows

Two of the most widely recognized supplements for brain health, lion's mane mushroom and ginkgo biloba, work through fundamentally different mechanisms, and the distinction matters when you are deciding what to take. Lion's mane targets the brain's capacity to build and maintain neurons. Ginkgo biloba targets circulation. Understanding which mechanism is more relevant to what happens in the aging brain after 45 is the clearest way to evaluate these two options against each other.

How lion's mane mushroom supports memory and cognition

Lion's mane mushroom (Hericium erinaceus) contains two classes of bioactive compounds not found in other fungi: hericenones, which are found in the fruiting body, and erinacines, which are found in the mycelium. Both stimulate the synthesis of Nerve Growth Factor (NGF), a protein that governs the survival, maintenance, and differentiation of neurons in the central and peripheral nervous systems.

NGF is not optional for brain health. It supports the structure of the hippocampus, the region most directly involved in forming and retrieving memories, and its levels decline measurably with age. Research cited in the Alzheimer's Drug Discovery Foundation's Cognitive Vitality database identifies reduced NGF signaling as a factor in the neuronal atrophy associated with Alzheimer's disease progression. Lion's mane is one of the few dietary compounds with a characterized mechanism for stimulating NGF synthesis in human neural tissue.

Erinacines cross the blood-brain barrier, which is the critical distinction between mycelium-derived and fruiting body-derived compounds. Hericenones from the fruiting body have demonstrated NGF-stimulating activity in cell studies but have lower confirmed CNS penetration than erinacines. A comprehensive formula using the fruiting body extract, as Sharper Memory does with its 450 mg lion's mane fruiting body extract, provides the full spectrum of bioactive compounds alongside structural polysaccharides that support immune function in neural tissue.

What the clinical trials on lion's mane actually show

The foundational human clinical trial on lion's mane and cognition was conducted by Mori, Inatomi, Ouchi, Azumi, and Tuchida, published in Phytotherapy Research in 2009 (PMID: 19001767). Thirty subjects aged 50 to 80 diagnosed with mild cognitive impairment were randomized into two groups in a double-blind, placebo-controlled design. The treatment group took four 250 mg tablets of Hericium erinaceus dry powder three times daily (3 g per day total) for 16 weeks. At weeks 8, 12, and 16, the lion's mane group showed significantly higher scores on the Revised Hasegawa Dementia Scale (HDS-R) compared to placebo. Scores declined significantly four weeks after discontinuation, indicating that continued supplementation was necessary to maintain benefit.

A 2019 study by Saitsu, Nishide, Kikushima, and colleagues, published in Biomedical Research (PMID: 30987921), examined 31 healthy older adults and found improvement in scores on the Kana Pick-Out Test, a standardized Japanese cognitive assessment, following oral intake of Hericium erinaceus over 12 weeks. The population here was not clinically impaired, which matters for the target audience of most supplement buyers.

A 2023 double-blind, parallel-group, placebo-controlled pilot study by Docherty, Doughty, and Smith, published in Nutrients (PMC10675414), examined the acute and chronic effects of lion's mane supplementation in healthy younger adults. The chronic arm found a trend toward reduced subjective stress alongside measurable improvements in cognitive performance. A 2025 double-blind RCT by Surendran and colleagues, published in Frontiers in Nutrition (doi: 10.3389/fnut.2025.1405796), confirmed acute improvements in cognitive performance following a standardized Hericium erinaceus extract in healthy adults.

An important note on limitations: most lion's mane trials are small, ranging from 30 to 77 participants, and are short in duration. The ADDF Cognitive Vitality database correctly identifies the evidence as promising but not yet replicated at large scale. That caveat applies here and is worth stating directly rather than hiding.

How ginkgo biloba works and where the evidence is strongest

Ginkgo biloba's mechanism is vascular, not neuroplastic. The standardized extract EGb 761, which is used in most clinical trials, contains flavonoid glycosides and terpenoids (ginkgolides and bilobalide) that act primarily as platelet-activating factor antagonists and antioxidants. The practical effect is improved cerebral blood flow, reduced oxidative stress in vascular tissue, and some modulation of neurotransmitter receptors including acetylcholine and NMDA.

The evidence for ginkgo is clearest in populations with existing pathology, specifically dementia and vascular cognitive impairment. A 2014 meta-analysis by Janssen, Sturtz, Skipka, and colleagues, published in Aging and Mental Health (PMID: 25506211), pooled data from seven randomized placebo-controlled trials involving 2,684 patients with dementia. Treatment with 120 to 240 mg per day of EGb 761 for 22 to 26 weeks produced standardized mean differences in cognition of -0.52 (95% CI: -0.98 to -0.05, p=0.03), activities of daily living of -0.44 (p less than 0.001), and global rating of -0.52 (p=0.01), all favoring EGb 761 over placebo. A 2025 meta-analysis by Riepe and Burkart, published in European Psychiatry (PMC12436692), confirmed similar findings specifically in patients with mild dementia, with medium to large standardized effects at 240 mg per day.

The World Federation of Societies of Biological Psychiatry lists EGb 761 with Grade 3, Level B evidence alongside acetylcholinesterase inhibitors and memantine for dementia treatment. This is a meaningful endorsement within a clinical context.

Where ginkgo biloba's evidence falls short for healthy aging adults

The critical limitation of ginkgo biloba is that its benefits are concentrated in populations who already have diagnosable cognitive impairment or dementia. The evidence for prevention in healthy adults is substantially weaker and, in the most rigorous trial conducted to date, essentially absent.

The Ginkgo Evaluation of Memory (GEM) study, led by Steven DeKosky and colleagues at the University of Virginia and published in JAMA in 2008 (PMID: 19017911), remains the largest and longest prevention trial of ginkgo biloba on record. It enrolled 3,069 community volunteers aged 75 and older, either with normal cognition (n=2,587) or mild cognitive impairment (n=482), at five academic medical centers across the United States. Participants were randomized to 120 mg twice daily of EGb 761 or placebo and followed for a median of 6.1 years. The trial found no statistically significant difference in dementia incidence between groups: 277 participants taking ginkgo developed dementia compared to 246 in the placebo group, a difference that was not significant. The study also found no effect on rate of progression to dementia in those who entered with mild cognitive impairment.

A separate randomized trial by DeKosky, Williamson, Fitzpatrick, and the GEM investigators, published in JAMA in December 2009 (PMID: 20040554), used the same cohort to test whether ginkgo slowed the rate of global or domain-specific cognitive decline in older adults without dementia. It did not.

These are not small studies with weak methodology. The GEM trials are among the most rigorous supplement prevention trials ever conducted. Their null findings in healthy and mildly impaired older adults do not mean ginkgo has no role in medicine. They mean that ginkgo's benefit is concentrated at the disease end of the spectrum, not at the prevention and healthy-aging end where most supplement users are operating.

Why the mechanism difference matters after 45

The aging brain after 45 faces two broad categories of challenge. The first is structural: neurons lose synaptic connections, axon density decreases, and NGF availability declines. The second is vascular: cerebral blood flow decreases and oxidative stress accumulates in the vascular system that supplies the brain.

Ginkgo biloba addresses the second category. It is a reasonable intervention for vascular cognitive impairment and has a meaningful evidence base in dementia populations where vascular pathology is prominent. For someone with documented cerebrovascular disease, ginkgo's mechanism is well-targeted.

Lion's mane addresses the first category. NGF stimulation supports neuronal survival and synaptic plasticity directly, independent of vascular status. This is the mechanism most relevant to the early, pre-pathological changes in the brain that begin in midlife: the gradual thinning of synaptic density, the slowing of neural communication, the decline in the brain's capacity to form new connections. As covered in what actually happens to your brain in your 50s, these structural changes begin earlier than most people expect, and they are the changes that drive everyday memory complaints well before any clinical diagnosis applies.

The other factor is specificity of evidence. Ginkgo's strongest results are in people who already have moderate-to-severe dementia or clinically diagnosed MCI. The GEM trials found no benefit in people who did not yet have these diagnoses. Lion's mane trials have included populations with MCI and, more recently, healthy adults, and have found positive signals in both. For someone who is 50 and cognitively healthy but wants to stay that way, lion's mane's evidence base is more directly applicable to their situation.

How lion's mane works better alongside the other ingredients in Sharper Memory

The case for lion's mane strengthens further when it is considered alongside complementary ingredients rather than in isolation. Sharper Memory pairs lion's mane with citicoline, which raises levels of acetylcholine, the neurotransmitter most directly associated with memory encoding and retrieval. As explained in the overview of acetylcholine and memory, acetylcholine production depends on the availability of choline precursors in the brain. Citicoline raises both choline and cytidine levels, directly supporting the neurotransmitter system that benefits most from the improved synaptic connectivity that lion's mane supports via NGF.

This is a physiologically coherent pairing. NGF supports the structure and density of the neurons and synapses that acetylcholine travels across. Citicoline ensures that those synapses have the neurotransmitter they need to function. The two mechanisms reinforce each other in a way that neither ginkgo's vascular mechanism nor citicoline alone would achieve.

The formula also includes PQQ (pyrroloquinoline quinone), which supports mitochondrial function and biogenesis in neurons. Lion's mane improves the structural capacity of neurons to form connections; PQQ supports the cellular energy system those neurons need to operate efficiently. Bacopa monnieri contributes adaptogen effects and synaptic modulation through a distinct pathway involving dendritic branching in the hippocampus. The Brain Power Probiotic Blend addresses the gut-brain axis, which modulates neurotransmitter precursor availability and systemic inflammation, both of which influence cognitive performance.

Ginkgo biloba, taken alone, does not interact with any of these pathways in a synergistic way. Its vascular mechanism is essentially parallel to, rather than multiplicative with, neuroplasticity support, neurotransmitter support, or mitochondrial support. This is not a flaw in ginkgo. It is simply a reflection of what it does and where in the system it operates. Lion's mane, by contrast, sits at the center of a network of neuroplasticity-adjacent mechanisms that compound each other.

What to look for in a lion's mane supplement

Not all lion's mane products are equivalent. Several variables determine whether a supplement is likely to deliver the kind of bioactive compound exposure studied in clinical trials.

Fruiting body versus mycelium is the most important distinction. Hericenones are present only in the fruiting body. Erinacines are found in the mycelium. Some products use mycelium grown on a grain substrate and contain significant amounts of starch from that substrate rather than the mushroom tissue itself. A fruiting body extract will contain hericenones and a more concentrated dose of active mushroom compounds per gram. Sharper Memory uses a 450 mg fruiting body extract, which aligns with the fruiting body preparations studied in the Mori 2009 and related trials.

Delivery format also matters. Sharper Memory uses a liposomal delivery system for its active ingredients. As discussed in the post on liposomal delivery and bioavailability, liposomal encapsulation protects compounds from degradation before absorption and improves uptake across mucosal and cellular membranes. The practical implication is that a lower listed dose of a liposomal ingredient may deliver more bioavailable compound than a higher dose in a standard capsule formulation.

Standardization and third-party testing are baseline requirements. Without a certificate of analysis from an independent lab, there is no reliable way to confirm that the listed amount of active compound is present in the capsule.

The direct answer: which is better for memory in healthy aging adults?

For adults who are cognitively healthy and want to support memory and cognitive function as they age, lion's mane has the more relevant mechanism and the more applicable evidence base. Its NGF-stimulating compounds address the neuroplasticity decline that begins in midlife, its clinical trials have been conducted in both MCI and healthy populations, and its mechanism combines productively with the other neuroplasticity and neurotransmitter-support ingredients in a comprehensive formula.

Ginkgo biloba is not without merit. For adults with vascular risk factors, documented cerebrovascular disease, or existing cognitive impairment, ginkgo's evidence base, particularly in dementia populations, is well-supported. The World Federation of Societies of Biological Psychiatry's Grade B recommendation for EGb 761 in dementia is not a small thing. But for the 52-year-old who is cognitively intact and wants to stay that way, the GEM trials are a direct and rigorous answer: ginkgo did not prevent cognitive decline in exactly this population over six years of careful observation.

Lion's mane has not been tested at that scale or duration. Its evidence base is earlier-stage. But the mechanism is better targeted to the neuroplasticity changes of healthy aging, the clinical signals in relevant populations are positive, and the combination with citicoline, PQQ, and Bacopa in Sharper Memory addresses multiple cognitive pathways in a way that a single-ingredient ginkgo product does not.

For anyone researching this decision seriously, the best approach is to read the primary sources, consult a healthcare provider familiar with cognitive health, and weigh the evidence by population applicability, not just by whether a study found a positive result. The GEM trial found positive results in dementia populations and null results in healthy adults. That distinction should inform how the evidence is applied. As the overview of brain energy and aging covers, supporting the brain proactively, before decline becomes clinically measurable, is where nutritional interventions have their best opportunity to make a difference.